Vascular smooth muscle cell hypertrophy induced by glycosylated human oxyhaemoglobin.
1. Nonenzymatic protein glycosylation is a possible mechanism contributing to oxidative stress and vascular disease in diabetes. In this work, the influence of 14%-glycosylated human oxyhaemoglobin (GHHb), compared to the non-glycosylated protein (HHb), was studied on several growth parameters of rat cultured vascular smooth muscle cells (VSMC). A role for reactive oxygen species was also analysed. 2. Treatment of VSMC for 48 h with GHHb, but not with HHb, increased planar cell surface area in a concentration dependent manner. The threshold concentration was 10 nM, which increased cell size from 7965+/-176 to 9411+/-392 microm2. Similarly, only GHHb enhanced protein content per well in VSMC cultures. 3. The planar surface area increase induced by 10 nM GHHb was abolished by superoxide dismutase (SOD; 50 200 u ml(-1)), deferoxamine (100 nM-100 microM), or dimethylthiourea (1 mM), while catalase (50 200 u ml(-1)) or mannitol (1 mM) resulted in a partial inhibition of cell size enhancement. 4. When a known source of oxygen free radicals was administered to VSMC, the xanthine/xanthine oxidase system, the results were analogous to those produced by GHHb. Indeed, enhancements of cell size were observed, which were inhibited by SOD, deferoxamine, or catalase. 5. These results indicate that, at low concentrations, GHHb induces hypertrophy in VSMC, this effect being mediated by superoxide anions, hydrogen peroxide, and/or hydroxyl radicals. Therefore, glycosylated proteins can have a role in the development of the structural vascular alterations associated to diabetes by enhancing oxidative stress.
Peiró
C
C
Departamento de Farmacología y Terapéutica, Facultad de Medicina, Universidad Autónoma de Madrid, Spain.
Angulo
J
J
Rodríguez-Mañas
L
L
Llergo
J L
JL
Vallejo
S
S
Cercas
E
E
Sánchez-Ferrer
C F
CF
D000818:Animals; D015415:Biomarkers; D002455:Cell Division / Q000187:drug effects; D006442:Glycated Hemoglobin / Q000494:pharmacology; D006801:Humans; D006984:Hypertrophy / Q000139:chemically induced*; D009131:Muscle, Smooth, Vascular / Q000187:drug effects*; D010108:Oxyhemoglobins / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012709:Serum Albumin / Q000494:pharmacology; D014969:Xanthine Oxidase / Q000494:pharmacology
D015415:Biomarkers; D006442:Glycated Hemoglobin; D010108:Oxyhemoglobins; D012709:Serum Albumin; D014969:Xanthine Oxidase